Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 21521314)

1.

What is the role of alternative biomarkers for coronary heart disease?

Garg A.

Clin Endocrinol (Oxf). 2011 Sep;75(3):289-93. doi: 10.1111/j.1365-2265.2011.04045.x.

PMID:
21521314
2.

Assessing coronary heart disease risk with traditional and novel risk factors.

Wilson PW.

Clin Cardiol. 2004 Jun;27(6 Suppl 3):III7-11. Review.

PMID:
15239485
3.

An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.

Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH Jr, Sorlie P, Diao G, Sharrett AR.

Arch Intern Med. 2006 Jul 10;166(13):1368-73.

PMID:
16832001
4.

Predictors of coronary heart disease events among asymptomatic persons with low low-density lipoprotein cholesterol MESA (Multi-Ethnic Study of Atherosclerosis).

Blankstein R, Budoff MJ, Shaw LJ, Goff DC Jr, Polak JF, Lima J, Blumenthal RS, Nasir K.

J Am Coll Cardiol. 2011 Jul 19;58(4):364-74. doi: 10.1016/j.jacc.2011.01.055.

5.

Biomarkers for predicting postmenopausal coronary heart disease.

Spoletini I, Vitale C, Rosano GM.

Biomark Med. 2011 Aug;5(4):485-95. doi: 10.2217/bmm.11.51. Review.

PMID:
21861670
6.
7.

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD.

N Engl J Med. 2000 Oct 19;343(16):1148-55.

8.

Are novel serum biomarkers informative?

Wilkins JT, Lloyd-Jones DM.

Med Clin North Am. 2012 Jan;96(1):1-11. doi: 10.1016/j.mcna.2012.01.017. Review.

PMID:
22391247
9.

Family history and premature coronary heart disease.

Eaton CB, Bostom AG, Yanek L, Laurino JP, McQuade W, Hume A, Selhub J.

J Am Board Fam Pract. 1996 Sep-Oct;9(5):312-8.

PMID:
8884668
10.

Inflammatory markers in coronary heart disease.

Madjid M, Willerson JT.

Br Med Bull. 2011;100:23-38. doi: 10.1093/bmb/ldr043. Epub 2011 Oct 18. Review.

PMID:
22010105
11.

Multimarker prediction of coronary heart disease risk: the Women's Health Initiative.

Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, Limacher MC, Lloyd-Jones DM, Margolis KL, Robinson JG.

J Am Coll Cardiol. 2010 May 11;55(19):2080-91. doi: 10.1016/j.jacc.2009.12.047.

12.

Cardiovascular disease: strategies for risk assessment and modification.

Braun LT.

J Cardiovasc Nurs. 2006 Nov-Dec;21(6 Suppl 1):S20-42; quiz S43-5. Review.

PMID:
17293747
13.

PLAC test for identification of individuals at increased risk for coronary heart disease.

Hoogeveen RC, Ballantyne CM.

Expert Rev Mol Diagn. 2005 Jan;5(1):9-14.

PMID:
15723587
14.

Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome.

Bianchi C, Penno G, Malloggi L, Barontini R, Corfini M, Giovannitti MG, Di Cianni G, Del Prato S, Miccoli R.

Nutr Metab Cardiovasc Dis. 2008 Jan;18(1):31-8. Epub 2007 Apr 8.

PMID:
17420118
15.

Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.

Anderson JL.

Am J Cardiol. 2008 Jun 16;101(12A):23F-33F. doi: 10.1016/j.amjcard.2008.04.015. Review.

PMID:
18549868
17.

Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk.

Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM.

Circulation. 2008 Feb 12;117(6):823-31. doi: 10.1161/CIRCULATIONAHA.107.719369. Epub 2008 Jan 28.

19.

C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.

Tsimikas S, Willerson JT, Ridker PM.

J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C19-31. Review.

20.

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators.

J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk